IgA Nephropathy Treatment Efficacy: MMF and HCQ Combination Therapy

83 patients receiving mycophenolate mofetil plus hydroxychloroquine and 94 receiving MMF alone were analyzed in a multicenter retrospective cohort study. The dataset likely contains patient outcomes, including complete and overall remission rates at 12 months, as well as adverse events. Author Yang Yang published the data on figshare under a CC-BY-4.0 license.

Use Cases

• Compare complete remission rates between combination and monotherapy groups based on the 12-month outcome data.
• Analyze the association between baseline proteinuria levels and treatment response based on the subgroup analysis mentioned.
• Model the probability of achieving overall remission over time using the Kaplan-Meier analysis results described.
• Investigate the safety profile of combination therapy based on the reported incidence of adverse events.

Strengths

• Data is from a multicenter study, potentially increasing generalizability.
• Specific patient inclusion criteria are detailed, such as biopsy-confirmed IgAN and eGFR > 45 ml/min/1.73 m².
• Results include statistically significant odds ratios and p-values for primary outcomes.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The 262.8 KB file size suggests a limited scope of data.

Provenance

Source

figshare, author Yang Yang.

Collection Method

Multicenter retrospective cohort study using propensity score matching.

Freshness

Last updated 2026-03-18 07:05:54; freshness should be verified.